0.00Open0.00Pre Close0 Volume0 Open Interest44.50Strike Price0.00Turnover0.00%IV20.46%PremiumNov 8, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma69.07Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Bristol-Myers Squibb Stock Discussion
Abbott Laboratories (ABT US) $Abbott Laboratories (ABT.US)$
Daily Chart -[BULLISH ↗ **]ABT US is currently holding above short term ascending trendline support. As long as price is holding above 117.30 support, a further push higher towards 1st resistance at 123.80 then next resistance at 131.20 is expected. Technical indicators are advocating for a bullish scenario as well.
Altern...
📌 This Week’s PDUFA:
$ZLDPF: 🤔
‣ Dasiglucagon
‣ Congenital Hyperinsulinism
‣ PDUFA: 10/08/24
📣 Last Week’s PDUFA decisions:
$Biofrontera (BFRI.US)$ : Approved ✅
⇨ Ameluz
‣ Actinic keratosis
‣ PDUFA: 10/04/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : Approved ✅
⇨ Neoadjuvant Opdivo (nivolumab) + Chemo
‣ NSCLC (perioperative treatment)
‣ PDUFA: 10/08/24
Gapping up
$Bristol-Myers Squibb (BMY.US)$ Shares jumped 3.8% after the FDA approved Cobenfy as a new treatment for schizophrenia in adults, marking the first novel treatment for the mental disorder in several decades.
$Wynn Resorts (WYNN.US)$ Shares climbed 1.7% following an upgrade to overweight from equal weight by Morgan Stanley, which highlighted the company's strong fundamentals compared to its competitors...
lets See If It Get Some Love Tomorrow To Close The Week
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...
No comment yet